Skip Ribbon Commands
Skip to main content

Myelodysplastic Syndrome

Myelodysplastic Syndrome - How to prevent?

Myelodysplastic Syndrome - Treatments

​Based on the blood counts and findings from the bone marrow biopsy, patients can be categorized into lower and higher risk MDS. These categories are useful to help predict risk of progression to acute leukemia and estimating survival. 

Treatment strategy for MDS will take into consideration the disease risk category, patients’ symptoms and fitness for treatment. 

Patients with MDS may receive one or more of the treatment options below 
  • Blood transfusions 
    • Transfusions of red blood cells or platelets are given to relieve symptoms or when the numbers are dangerously low 
    • In SGH, most patients are able to receive their regular blood transfusions as an outpatient at our Haematology Centre
  • Haematopoietic growth factors 
    • The most commonly prescribed growth factor is high dose erythropoietin which helps to stimulate red cell production and reduce transfusion needs.
  • Immunosuppressive therapies 
    • Lenalidomide – some patients have a specific subtype of MDS with a chromosomal abnormality called deletion 5q. They may be prescribed an oral therapy called lenalidomide to improve their blood counts 
    • In selected patients with MDS, especially those with low risk, doctors may prescribe a combination of immunosuppressive therapies such as ciclosporin and anti-thymocyte globulin 
  • Hypomethylating agent 
    • The most commonly used hypomethylating agent in Singapore is azacitidine. 
    • It is a type of low intensity chemotherapy that has been shown to enable bone marrow cells to develop more normally and may help to delay progression to acute leukemia and prolong survival. 
  • Allogeneic stem cell transplant 
    • It is the only treatment that has been shown to cure MDS but it is associated with many severe complications 
    • It is usually recommended to patients with high risk disease and are fit for intensive treatment 

As the oldest and most established haematology department in Singapore, we have a dedicated group of doctors who specialize not only in the treatment of myelodysplastic syndrome, but also have access to new medication through clinical trials. For high-risk patients and in event of transformation to leukaemia, suitable patients will be transition to the haematopoietic stem cell transplant team. 


Myelodysplastic Syndrome - Preparing for surgery

Myelodysplastic Syndrome - Post-surgery care

Myelodysplastic Syndrome - Other Information

The information provided is not intended as medical advice. Terms of use. Information provided by SingHealth

Discover articles,videos, and guides afrom Singhealth's resources across the web. These information are collated, making healthy living much easier for everyone.